Inhibrx Biosciences, Inc. (INBX) is a Biotechnology company in the Healthcare sector, currently trading at $83.19. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: INBX trades at a trailing Price-to-Earnings (P/E) of -7.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.25.
Financials: revenue is $1M, +147.9%/yr average growth. Net income is $140M (loss), growing at +208.2%/yr. Net profit margin is -10773.5% (negative). Gross margin is -91% (-60.3 pp trend).
Balance sheet: total debt is $107M against $8M equity (Debt-to-Equity (D/E) ratio 13.39, leveraged). Current ratio is 3.93 (strong liquidity). Debt-to-assets is 73.1%. Total assets: $146M.
Analyst outlook: 3 / 5 analysts rate INBX as buy (60%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 33/100 (Fail), Moat 12/100 (Fail), Future 55/100 (Partial), Income 10/100 (Fail).
